RU2014143271A - Базовая инсулинотерапия - Google Patents
Базовая инсулинотерапия Download PDFInfo
- Publication number
- RU2014143271A RU2014143271A RU2014143271A RU2014143271A RU2014143271A RU 2014143271 A RU2014143271 A RU 2014143271A RU 2014143271 A RU2014143271 A RU 2014143271A RU 2014143271 A RU2014143271 A RU 2014143271A RU 2014143271 A RU2014143271 A RU 2014143271A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- prolonged
- diabetes
- therapeutically effective
- type
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract 70
- 102000004877 Insulin Human genes 0.000 title claims abstract 35
- 108090001061 Insulin Proteins 0.000 title claims abstract 35
- 229940125396 insulin Drugs 0.000 title claims abstract 35
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 43
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract 30
- 206010056997 Impaired fasting glucose Diseases 0.000 claims abstract 30
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract 30
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract 27
- 201000010099 disease Diseases 0.000 claims abstract 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 15
- 229940079593 drug Drugs 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims abstract 11
- 239000003538 oral antidiabetic agent Substances 0.000 claims abstract 11
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 3
- 230000002035 prolonged effect Effects 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 6
- 108010057186 Insulin Glargine Proteins 0.000 claims 5
- 229960002869 insulin glargine Drugs 0.000 claims 5
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000005022 packaging material Substances 0.000 claims 4
- 108010092217 Long-Acting Insulin Proteins 0.000 claims 3
- 102000016261 Long-Acting Insulin Human genes 0.000 claims 3
- 229940100066 Long-acting insulin Drugs 0.000 claims 3
- 229940109239 creatinine Drugs 0.000 claims 3
- 238000002430 laser surgery Methods 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 108010089308 Insulin Detemir Proteins 0.000 claims 2
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims 2
- 206010027525 Microalbuminuria Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 108010050259 insulin degludec Proteins 0.000 claims 2
- 229960004225 insulin degludec Drugs 0.000 claims 2
- 229960003948 insulin detemir Drugs 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 claims 2
- 238000011301 standard therapy Methods 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616768P | 2012-03-28 | 2012-03-28 | |
| US61/616,768 | 2012-03-28 | ||
| US201261619641P | 2012-04-03 | 2012-04-03 | |
| US61/619,641 | 2012-04-03 | ||
| US201261624598P | 2012-04-16 | 2012-04-16 | |
| US61/624,598 | 2012-04-16 | ||
| US201261645909P | 2012-05-11 | 2012-05-11 | |
| US61/645,909 | 2012-05-11 | ||
| US201261701911P | 2012-09-17 | 2012-09-17 | |
| US61/701,911 | 2012-09-17 | ||
| PCT/EP2013/056661 WO2013144273A1 (en) | 2012-03-28 | 2013-03-28 | Basal insulin therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014143271A true RU2014143271A (ru) | 2016-05-20 |
Family
ID=48044781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014143271A RU2014143271A (ru) | 2012-03-28 | 2013-03-28 | Базовая инсулинотерапия |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150065421A1 (enExample) |
| EP (1) | EP2830650A1 (enExample) |
| JP (1) | JP2015512908A (enExample) |
| KR (1) | KR20150001757A (enExample) |
| CN (1) | CN104334183A (enExample) |
| AU (1) | AU2013241776B2 (enExample) |
| CA (1) | CA2865823A1 (enExample) |
| HK (1) | HK1201155A1 (enExample) |
| IN (1) | IN2014KN02335A (enExample) |
| MX (1) | MX2014011687A (enExample) |
| RU (1) | RU2014143271A (enExample) |
| SG (1) | SG11201405433XA (enExample) |
| WO (1) | WO2013144273A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017108943A1 (en) * | 2015-12-23 | 2017-06-29 | Sanofi-Aventis Deutschland Gmbh | Cardiac metabolic effect of lantus |
| MA46890A (fr) | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
| EP3544683A1 (en) | 2016-11-28 | 2019-10-02 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| WO2018096164A1 (en) * | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| US20190357853A1 (en) * | 2018-05-24 | 2019-11-28 | Lizheng Shi | Diabetes risk engine and methods thereof for predicting diabetes progression and mortality |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0309154D0 (en) * | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| PH12012502524A1 (en) * | 2010-06-24 | 2014-02-10 | Boehringer Ingelheim Int | Diabetes therapy |
-
2013
- 2013-03-28 IN IN2335KON2014 patent/IN2014KN02335A/en unknown
- 2013-03-28 JP JP2015502348A patent/JP2015512908A/ja not_active Ceased
- 2013-03-28 CA CA2865823A patent/CA2865823A1/en not_active Abandoned
- 2013-03-28 CN CN201380028029.4A patent/CN104334183A/zh active Pending
- 2013-03-28 WO PCT/EP2013/056661 patent/WO2013144273A1/en not_active Ceased
- 2013-03-28 US US14/387,791 patent/US20150065421A1/en not_active Abandoned
- 2013-03-28 EP EP13713425.0A patent/EP2830650A1/en not_active Withdrawn
- 2013-03-28 AU AU2013241776A patent/AU2013241776B2/en not_active Expired - Fee Related
- 2013-03-28 KR KR20147028987A patent/KR20150001757A/ko not_active Withdrawn
- 2013-03-28 RU RU2014143271A patent/RU2014143271A/ru not_active Application Discontinuation
- 2013-03-28 SG SG11201405433XA patent/SG11201405433XA/en unknown
- 2013-03-28 HK HK15101611.0A patent/HK1201155A1/xx unknown
- 2013-03-28 MX MX2014011687A patent/MX2014011687A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150001757A (ko) | 2015-01-06 |
| SG11201405433XA (en) | 2014-10-30 |
| WO2013144273A1 (en) | 2013-10-03 |
| AU2013241776A1 (en) | 2014-10-16 |
| CN104334183A (zh) | 2015-02-04 |
| IN2014KN02335A (enExample) | 2015-05-01 |
| EP2830650A1 (en) | 2015-02-04 |
| HK1201155A1 (en) | 2015-08-28 |
| US20150065421A1 (en) | 2015-03-05 |
| JP2015512908A (ja) | 2015-04-30 |
| MX2014011687A (es) | 2015-05-11 |
| AU2013241776B2 (en) | 2017-11-02 |
| CA2865823A1 (en) | 2013-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bianchi et al. | Metabolic memory and individual treatment aims in type 2 diabetes–outcome-lessons learned from large clinical trials | |
| Rocha et al. | Metformin in patients with chronic kidney disease: strengths and weaknesses | |
| Moussavi et al. | Management of hyperkalemia with insulin and glucose: pearls for the emergency clinician | |
| Zimmet | Preventing diabetic complications: a primary care perspective | |
| Solini et al. | Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study | |
| Pun et al. | Sudden cardiac death in hemodialysis patients: a comprehensive care approach to reduce risk | |
| JP2015164964A5 (enExample) | ||
| Kaufmann et al. | Association of metformin and other diabetes medication use and the development of new-onset dry age-related macular degeneration: a case–control study | |
| Haungsaithong et al. | The changes in mean platelet volume after using of antiplatelet drugs in acute ischemic stroke: a randomized controlled trial | |
| CN104334183A (zh) | 基底胰岛素治疗 | |
| Balakumar et al. | Reversal of dabigatran with idarucizumab in acute subarachnoid hemorrhage | |
| Davari et al. | The prescription pattern of anti-diabetic medication and glycemic control in type 2 diabetes in Iran; a patient-level study | |
| DeFronzo et al. | Sodium–glucose cotransporter 2 inhibitors and the kidney | |
| Huang et al. | A Retrospective Longitudinal Cohort Study of Antihypertensive Drug Use and New‐Onset Diabetes in Taiwanese Patients | |
| CN103025334A (zh) | 抗糖尿病组合物和方法 | |
| Dodson | Medical treatment for diabetic retinopathy: do the FIELD microvascular study results support a role for lipid lowering? | |
| El Houari et al. | A survival case in a severe amlodipine intoxication | |
| KR20210137154A (ko) | 혈액투석 환자에서의 사용을 위한 칼륨-결합제 | |
| カトウヨシカネ et al. | Current topics of possible pharmacotherapy for chronic kidney disease (CKD) and diabetes | |
| Venos et al. | My patient's diabetic kidney disease has progressed to stage 4; Should I discontinue metformin? | |
| Al-Dughaishi et al. | Successful direct adsorption of lipoproteins (DALI) apheresis during pregnancy in an Omani woman with homozygous familial hypercholesterolemia | |
| Farolfi et al. | A 98-year-old male with paroxysmal atrial fibrillation treated for COVID-19 at home | |
| Mohammadi et al. | Delayed Symptoms of Rodenticide Poisoning in a 16-Year-Old: A Case Report | |
| Rognant | Is there an interest in implementing a multidisciplinary clinic or renal care network to improve the prognosis of patients with chronic kidney disease? | |
| Hamidi | Apixaban for Venous Thromboembolism in Patients with End-Stage Kidney Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180109 |